Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07258836 · ClinicalTrials.gov registry record · Phase 1
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
A Phase 1 study of Healthy and Neoplasms, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 5
- Study locations
NCT07258836: Recruiting Phase 1 study of Healthy and Neoplasms, sponsored by Eli Lilly and Company.
NCT07258836 is a Phase 1 study of Healthy and Neoplasms that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 41 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07258836, a Phase 1 study of Healthy and Neoplasms, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Primary Outcome
Evaluation of AEs regardless of causality, will be reported in the Reported AEs module
Interventions
- DRUG LY4214835
Study Locations (5)
Massachusetts
- Boston Medical Center - Boston
- Massachusetts General Hospital (MGH) - Charlestown
Connecticut
- Invicro - New Haven
Michigan
- BAMF Health Inc. - Grand Rapids
New York
- Ichor Research - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT07258836 shows while recruiting
NCT07258836 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which LY4214835 is the first listed.
NCT07258836 lists 5 locations in 4 states (Massachusetts, Connecticut, Michigan).
Frequently Asked Questions
What is clinical trial NCT07258836 about?
NCT07258836 is a clinical study titled "A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer". The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
What is the current status of trial NCT07258836?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2025-12-22. Estimated completion is 2027-01.
What conditions does trial NCT07258836 study?
This clinical trial studies the following conditions: Healthy, Neoplasms.
What interventions are being tested in trial NCT07258836?
The interventions under investigation include: LY4214835 (DRUG).
Who is sponsoring clinical trial NCT07258836?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07258836 being conducted?
This trial has 5 study locations across Connecticut, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07258836's enrollment target sits among peer trials
41 536th of 1090 higher than 552 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI